Simmitecan hydrochloride

Cat. No.: HY-107133: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent.

For research use only. We do not sell to patients.

Simmitecan hydrochloride Chemical Structure

CAS No. : 1247847-78-4

Size		Stock
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Topoisomerase Isoform Specific Products:

View All Isoforms

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

Biological Activity
Purity & Documentation
References
Customer Review

Description	Simmitecan hydrochloride, a 9-substituted lipophilic Camptothecin (HY-16560) derivative, is a potent topoisomerase I inhibitor. Simmitecan hydrochloride is an anticancer agent^[1]^[2].
In Vitro	Simmitecan hydrochloride weak inhibitory effects on CYP2D6 (IC₅₀: 32.9 μM) and moderate inhibitory effects on CYP3A4 (IC₅₀: 8.95 μM)^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Simmitecan hydrochloride Related Antibodies
In Vivo	Simmitecan hydrochloride (3.75, 7.5 and 15 mg/kg, i.v. bolus) shows mean elimination half-life t_1/2 of approximately 1.4 h in SD rats^[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight	635.15
Formula	C₃₄H₃₉ClN₄O₆
CAS No.	1247847-78-4
SMILES	[H]Cl.CC[C@]1(O)C(C=C2N3CC4=CC5=C(C=CC(OC(N6CCC(N7CCCCC7)CC6)=O)=C5CC=C)N=C42)=C(COC1=O)C3=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (269 KB) Handling Instructions (2659 KB)
References	[1]. Rini B, et al. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma. Ann Oncol. 2014 Sep;25(9):1794-1799. [Content Brief] [2]. Hu ZY, et al. Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals. Acta Pharmacol Sin. 2013 Nov;34(11):1437-48. [Content Brief]